## Barbara Banelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7901752/publications.pdf

Version: 2024-02-01

159585 233421 2,222 65 30 45 citations h-index g-index papers 68 68 68 3775 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Multidrug Approach to Modulate the Mitochondrial Metabolism Impairment and Relative Oxidative Stress in Fanconi Anemia Complementation Group A. Metabolites, 2022, 12, 6.	2.9	8
2	In uveal melanoma $\widehat{Gl}$ -protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than $\widehat{Gl}$ -protein GNAQ mutations. European Journal of Cancer, 2022, 170, 27-41.	2.8	15
3	Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 459-468.	2.5	4
4	IFN- $\hat{I}^3$ upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade. Cellular and Molecular Immunology, 2020, 17, 410-411.	10.5	28
5	A Methanol Extract of Scabiosa atropurpurea Enhances Doxorubicin Cytotoxicity against Resistant Colorectal Cancer Cells In Vitro. Molecules, 2020, 25, 5265.	3.8	10
6	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunology, Immunotherapy, 2020, 69, 653-662.	4.2	16
7	Phenotypic characterization of tumor CTLA-4 expression in melanoma tissues and its possible role in clinical response to Ipilimumab. Clinical Immunology, 2020, 215, 108428.	3.2	15
8	Targeting of Histone Demethylases KDM5A and KDM6B Inhibits the Proliferation of Temozolomide-Resistant Glioblastoma Cells. Cancers, 2019, 11, 878.	3.7	41
9	Epigenetics, Public Health, Lifestyle, andÂChemoprevention. , 2019, , 395-418.		O
10	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. Cancer Immunology, Immunotherapy, 2019, 68, 97-107.	4.2	61
11	Complement component C5a induces aberrant epigenetic modifications in renal tubular epithelial cells accelerating senescence by Wnt4/ $\hat{l}^2$ catenin signaling after ischemia/reperfusion injury. Aging, 2019, 11, 4382-4406.	3.1	66
12	Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma. Genes Chromosomes and Cancer, 2018, 57, 387-400.	2.8	21
13	Immune Checkpoints and Innovative Therapies in Glioblastoma. Frontiers in Oncology, 2018, 8, 464.	2.8	70
14	Epigenetic Targeting of Glioblastoma. Frontiers in Oncology, 2018, 8, 448.	2.8	82
15	Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. Journal of Occupational Medicine and Toxicology, 2018, 13, 6.	2.2	32
16	CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. European Journal of Cancer, 2018, 97, 59-61.	2.8	22
17	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Frontiers in Immunology, 2017, 8, 386.	4.8	27
18	MicroRNA in Glioblastoma: An Overview. International Journal of Genomics, 2017, 2017, 1-16.	1.6	114

#	Article	IF	CITATIONS
19	Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells. Oncotarget, 2017, 8, 34896-34910.	1.8	48
20	Aberrantly methylated DNA regions lead to low activation of CD4+ T-cells in IgA nephropathy. Clinical Science, 2016, 130, 733-746.	4.3	39
21	Epigenetic dysregulation in neuroblastoma: A tale of miRNAs and DNA methylation. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2016, 1859, 1502-1514.	1.9	44
22	Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma. Medicine (United States), 2016, 95, e5447.	1.0	12
23	Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma. Oncotarget, 2016, 7, 83330-83341.	1.8	28
24	Dysregulated miR-671-5p / CDR1-AS / CDR1 / VSNL1 axis is involved in glioblastoma multiforme. Oncotarget, 2016, 7, 4746-4759.	1.8	103
25	Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines. Journal of Translational Medicine, 2015, 13, 324.	4.4	40
26	Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGMâ,, Platform. International Journal of Molecular Sciences, 2015, 16, 28765-28782.	4.1	35
27	Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention. BioMed Research International, 2015, 2015, 1-13.	1.9	49
28	The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Cell Cycle, 2015, 14, 3418-3429.	2.6	104
29	Quantitative Methylation Analysis of the PCDHB Gene Cluster. Methods in Molecular Biology, 2015, 1315, 189-200.	0.9	2
30	A novel multiplex pyrosequencing assay for genotyping functionally relevant CTLA-4 polymorphisms: Potential applications in autoimmunity and cancer. Human Immunology, 2014, 75, 730-739.	2.4	7
31	The IL-12RÎ <sup>2</sup> 2 gene functions as a tumor suppressor in human B cell malignancies. Journal of Clinical Investigation, 2014, 124, 2807-2807.	8.2	0
32	Epigenetic Silencing of DKK3 in Medulloblastoma. International Journal of Molecular Sciences, 2013, 14, 7492-7505.	4.1	18
33	Clinical Potentials of Methylator Phenotype in Stage 4 High-Risk Neuroblastoma: An Open Challenge. PLoS ONE, 2013, 8, e63253.	2.5	10
34	A pyrosequencing assay for the quantitative methylation analysis of the PCDHB gene cluster, the major factor in neuroblastoma methylator phenotype. Laboratory Investigation, 2012, 92, 458-465.	3.7	32
35	586 Comparison of DNA Methylation Markers in Advanced Stage, High Risk Neuroblastoma Patients. European Journal of Cancer, 2012, 48, S139-S140.	2.8	0
36	HOXA7, 9, and 10 are methylation targets associated with aggressive behavior in meningiomas. Translational Research, 2012, 160, 355-362.	5.0	34

#	Article	IF	CITATIONS
37	Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome. Journal of Cancer Research and Clinical Oncology, 2012, 138, 35-47.	2.5	37
38	Epigenetic mechanisms regulate $\hat{l}$ NP73 promoter function in human tonsil B cells. Molecular Immunology, 2011, 48, 408-414.	2.2	6
39	TAp73 is downregulated in oocytes from women of advanced reproductive age. Cell Cycle, 2011, 10, 3253-3256.	2.6	38
40	Toward an Epigenetic View of Our Musical Mind. Frontiers in Genetics, 2011, 2, 111.	2.3	9
41	MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis. Journal of Molecular Medicine, 2010, 88, 1041-1053.	3.9	37
42	Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the $\langle i \rangle SFN \langle i \rangle$ gene in advanced stage, highâ $\in$ risk, neuroblastic tumor patients. International Journal of Cancer, 2010, 126, 656-668.	5.1	35
43	Inflammation, HIF-1, and the Epigenetics That Follows. Mediators of Inflammation, 2010, 2010, 1-5.	3.0	30
44	Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer. Annals of Oncology, 2010, 21, 1237-1242.	1.2	29
45	Circulating Tumor Nucleic Acids: Perspective in Breast Cancer. Breast Care, 2010, 5, 75-80.	1.4	18
46	Involvement of GTA protein NC2 $\hat{l}^2$ in Neuroblastoma pathogenesis suggests that it physiologically participates in the regulation of cell proliferation. Molecular Cancer, 2008, 7, 52.	19.2	5
47	Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-Â in promyelocytic cells. International Immunology, 2008, 20, 1457-1466.	4.0	13
48	Down-regulation of DLX3 expression in MLL-AF4 childhood lymphoblastic leukemias is mediated by promoter region hypermethylation. Oncology Reports, 2007, , .	2.6	6
49	An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. International Journal of Cancer, 2007, 120, 39-47.	5.1	21
50	Meth-DOP-PCR: an assay for the methylation profiling of trace amounts of DNA extracted from bodily fluids. Laboratory Investigation, 2006, 86, 297-303.	3.7	3
51	Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors. Oncogene, 2005, 24, 5619-5628.	5.9	83
52	p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma. International Journal of Cancer, 2005, 114, 414-421.	5.1	64
53	DNA methylation in neuroblastic tumors. Cancer Letters, 2005, 228, 37-41.	7.2	21
54	Expression of the caspase-8 gene in neuroblastoma cells is regulated through an essential interferon-sensitive response element (ISRE). Cell Death and Differentiation, 2004, 11, 131-134.	11.2	46

#	Article	IF	CITATIONS
55	Caspase-8 Gene Expression in Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 157-167.	3.8	33
56	Inverse correlation between p16INK4A expression and NF-l <sup>o</sup> B activation in melanoma progression. Human Pathology, 2004, 35, 1029-1037.	2.0	13
57	The IL- $12R\hat{l}^2$ 2 gene functions as a tumor suppressor in human B cell malignancies. Journal of Clinical Investigation, 2004, 113, 1651-1659.	8.2	52
58	The IL- $12R\hat{l}^2$ 2 gene functions as a tumor suppressor in human B cell malignancies. Journal of Clinical Investigation, 2004, 113, 1651-1659.	8.2	27
59	Biological and clinical role of p73 in neuroblastoma. Cancer Letters, 2003, 197, 111-117.	7.2	19
60	Role of methylation in the control of $\hat{l}$ Np73 expression in neuroblastoma. Cell Death and Differentiation, 2002, 9, 343-345.	11.2	36
61	Expression of $\hat{l}$ Np73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death and Differentiation, 2002, 9, 246-251.	11.2	183
62	Expression and methylation of CASP8 in neuroblastoma: Identification of a promoter region. Nature Medicine, 2002, 8, 1333-1335.	30.7	76
63	Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene, 2000, 19, 4553-4556.	5.9	35
64	Identification of Unique Fragments in Overlapping Large-Insert Clones by Subtraction through Representational Difference Analysis. Analytical Biochemistry, 1999, 271, 204-207.	2.4	2
65	Different intracellular compartmentalization of TA and ΔNp73 in non-small cell lung cancer. International Journal of Oncology, 1992, 34, 449.	3.3	4